Диссертация (1140673), страница 17
Текст из файла (страница 17)
Atherosclerosis 2007;195:e210–5.113. Parissis J.T., Karavidas A., Bistola V., et al. Effects of levosimendan onflow-mediated vasodilation and soluble adhesion molecules in patientswith advanced chronic heart failure. Atherosclerosis 2008;197:278–82.114. Parmacek MS, Solaro RJ. Biology of the troponin complex in cardiacmyocytes. Prog Cardiovasc DisM. 2004;47:159–176.115. PatariczaJ., HohnJ., Petri A.
etal. Comparison of the vasorelaxing effect ofcromakalim and the new inodilator, levosimendan, in human isolated portalvein. J Pharm Pharmacol 2000; 52: 213-217.116. Pentikainen P., Antila S., Hayaha M. et al. Pharmacokinetics oflevosimendan in healthy volunteers and in patients with stable congestiveheart failure. Internal report: Orion Pharmaceutica; 1994February.
Report№.: 300103.117. Poder P, Heikkila J, Sandell E-R Effects of levosimendan in patients withacute myocardial infarct. A pilot study. Internal report: Orion Pharma; 1998April 9. Report №.: 3001019118. Pollesello P., Ovaska M., Kaivola J. et al. Binding of a new Ca2+ sensitizer,levosimendan, to recombinant human cardiac troponin C: a molecularmodelling, fluorescence probe, and proton nuclear magnetic resonancestudy. J Biol Chem 1994; 269: 28584-28590.106119.
Robertson I.M., Sun Y.B., Li M.X., Sykes B.D., A structural and functionalperspective into the mechanism of Ca ++-sensitizers that target the cardiactroponin complex. J Mol Cell Cardiol. 2010.120. Rump A.F.E., Acar D., Klaus W. A quantitative comparison of functionaland antiischaemic effects of the phosphodiesterasein- hibitors, arnrinone,milrinone and levosimendan in rabbit isolated hearts. Br J Pharmacoll 994;112: 757-762.121. Rump A.F.E., Acar D., Rosen R. et al. Functional and antiischaemic effectsof the phosphodiesterase inhibitor levosimendan in isolated rabbit hearts.Pharmacol Toxicol 1994; 74: 244-248.122.
Sandell E.P., Aalto Т., Antila S. et al. The effects of severe congestive heartfailure on the pharmacokinetics of levosimendan. Eur J Clin Pharmacol1997; 52 (Suppl.): 55.123. Sandell E.P., Hayha M., Antila S. et al. Pharmacokinetics of levosimendanin healthy volunteers and patients with congestive heart failure. JCardiovasc Pharmacol 1995; 26 (suppl 1): S57-S62.124. Sato S, Talukder MAH, Sugawara H, Sawada H, Endoh M. Effects oflevosimendan on myocardial contractility and Ca2+ transients in aequorinloaded right-ventricular papillary muscles and indo-1-loaded singleventricular cardiomyocytes of the rabbit.
J Mol Cell Cardiol 1998 ;30:1115-1128.125. Scheinin H. Pharmacokinetics of 24 hour levosimendan i.v. infusion inhealthy volunteers. Internal report: Orion Pharma; 2000. Report№.3001053.Semin. Cardiothorac. Vasc. Anesth. 8 (3) (2004) 185–211 (Review).126.
Slawsky M.T., Colucci W.S., Gottlieb S.S. et al. Acute hemodynamic andclinical effects of levosimendan in patients with severe heart failure.Curculation 2000; 102: 2222-2227.127. Sorsa T., Heikkinen S., Abbott M.B., et al. Binding of levosimendan, acalcium sensitizer, to cardiac troponin C.
J Biol Chem 2001;276:9337–43.107128. Sorsa T., Pollesello P., Rosevear P.R., et al., Stereoselective binding oflevosimendan to cardiac troponin C causes Ca2+-sensitization. Eur JPharmacol 2004;486:1–8.129. Sponga S., Ivanitskaia E., Potapov E., et al., Preoperative treatment withlevosimendan in candidates for mechanical circulatory support, ASAIO J.58 (2012) 6–11.130. Sundberg S., Antila S., Scheinin H. et al. Integrated pharmacokinetics andpharmacodynamics of the novel calcium sensitizer levosimendan asassessed by systolic time intervals. Int J Clin Pharmacol Ther 1998;36:629-635.131.
SundbergS.,LillebergJ.,NieminenM.S.etal.Hemodynamicandneurohumoral effects of levosimendan, a new calcium sensitizer, at rest andduring exercise in healthy men. Am J Cardiol 1995; 75:1061-1066.132. Szilágyi S., Pollesello P., Levijoki J., et al., The effects of levosimendan andOR-1896onisolatedhearts,myocyte-sizedpreparationsandphosphodiesterase enzymes of the guinea pig. Eur J Pharmacol 2004486:67-74133. Takahashi R., Talukder M.A., Endoh M. Effects of OR-1896, an activemetabolite of levosimendan, on contractile force and aequorin lighttransients in intact rabbit ventricular myocardium. J CardiovascPharmacol2000; 36:118-125.134.
Takahashi R., Talukder M.A., Endoh M. Inotropic effects of OR-1896, anactive metabolite of levosimendan, on canine ventricular myocardium. EurJPharmacol 2000; 400:103-112.135. Tasouli A, Papadopoulos K, Antoniou T, et al., Efficacy and safety ofperioperative infusion of levosimendan in patients with compromisedcardiac function undergoing open-heart surgery: importance of early use.Eur J Cardiothorac Surg.
2007 Oct;32(4):629-33. Epub 2007 Aug 15.108136. Theiss H.D., Grabmaier U, Kreissl N., et al., Preconditioning withlevosimendan before implantation of left ventricular assist devices, Artif.Organs 38 (2014) 231–234.137. Thygesen K, Alpert J, Jaffe A, et al Third universal definition of myocardialinfarction, European Heart Journal (2012) 33, 2551–2567138. Toller W, Algotsson L., Guarracino F., et al., Perioperative Use ofLevosimendan:BestPracticeinOperativeSettingsJournalofCardiothoracic and Vascular Anesthesia, Vol 27, No 2 (April), 2013: pp361-366139.
Toller W., Heringlake M., Guarracino F., et al. Preoperative andperioperative use of levosimendan in cardiac surgery: European expertopinion, International Journal of Cardiology 184 (2015) 323–336140. Tritapepe L., De Santis V., Vitale D., et al. Levosimendan pre-treatmentimproves outcomes in patients undergoing coronary artery bypass graftsurgery, British Journal of Anaesthesia 102 (2): 198–204 (2009)141. Ukkonen H., Saraste M., Akkila J. et al. Myocardial efficiency duringlevosimendan infusion in congestive heart failure.
Clinical Pharmacologyand Therapeutics 2000; 68: 522-531.142. Ukkonen H., Saraste M., Akkila J. et al. Myocardial efficiency duringcalcium sensitization with levosimendan: a noninvasive study with positronemission tomography and echocardiography in healthy volunteers. J ClinPharmacol Ther 1997; 61: 596-607.143. Varro A., Papp J.G. Classification of positive inotropic actions based onelectrophysiologic characteristics: where should calcium sensitizersbeplaced? J Cardiovasc Pharmacol 1995; 26 (Suppl. 1): 32-44.144. Weissman С, Pulmonary complications after cardiac surgery,145. WikbergT. Biotransformation of (±)-OR-1259 in man – chromatographiccharacterisation of the urinary metabolites.
Internal report: Orion Pharma;1992 March 12. Report №.: CR92032000053.109146. WikbergT. Profile of urinary metabolites of levosimendan in man. Internalreport: Orion Pharma; 1994 November 1. Report №.: CR94031200206.147. WikbergT., Salonen J., Lautala P. Metabolite profiles of intravenouslevosimendan in urine and faeces. Internal report: Orion Pharma; 2000April 28.
Report №.: PRE991032.148. Yokoshiki H., Katsube Y, Sunagawa M., Sperelakis N. The novel calciumsensitizer levosimendan activates the ATPsensitive K+ channel in ratventricular cells. J Pharmacol ExptTher 1997; 283: 375-383.149. Yokoshiki H., KatsubeY, Sunagawa M. etal. Levosimendan, a novel Ca2+sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterialmyocytes.
EurJ Pharmacol 1997; 333: 249-259.150. Zairis MN, Apostolatos C, Anastasiadis P. The effect of a calcium sensitizeror an inotrope or none in chronic low output decompensated heart failure:results from the Calcium Sensitizer or Inotrope or None in Low OutputHeart Failure Study (CASINO). (Abstract). J Am Coll Cardiol 2004;43Suppl. 1:206A-207A..
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
